A phase I study of cancer vaccine with NY-ESO-1 overlapping peptides in patients with advanced cancers expressing NY-ESO-1 antigen.
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Montanide ISA-51; Picibanil
- Indications Cancer
- Focus Adverse reactions
- 12 Oct 2016 Status changed from active, no longer recruiting to completed.
- 07 Apr 2013 Planned End Date changed from 1 Sep 2011 to 1 Sep 2014 as reported by University Hospital Medical Information Network - Japan.
- 09 May 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.